ProPhase Labs, Inc. (NASDAQ:PRPH) Sees Significant Decrease in Short Interest

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 230,600 shares, a decline of 49.6% from the April 30th total of 457,100 shares. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.2% of the company’s shares are short sold.

Institutional Trading of ProPhase Labs

Institutional investors and hedge funds have recently bought and sold shares of the stock. SVB Wealth LLC purchased a new position in ProPhase Labs during the fourth quarter worth about $36,000. HighTower Advisors LLC lifted its holdings in shares of ProPhase Labs by 32.2% in the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after acquiring an additional 57,736 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after purchasing an additional 42,793 shares during the period. Perritt Capital Management Inc increased its holdings in ProPhase Labs by 129.1% in the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after purchasing an additional 107,068 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in ProPhase Labs by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock valued at $217,000 after purchasing an additional 71,375 shares during the last quarter. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

ProPhase Labs Stock Performance

ProPhase Labs stock opened at $0.37 on Friday. The firm has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.48. The stock has a market cap of $15.16 million, a price-to-earnings ratio of -0.29 and a beta of -0.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. ProPhase Labs has a 1-year low of $0.22 and a 1-year high of $5.22.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings data on Tuesday, May 20th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.06. ProPhase Labs had a negative return on equity of 62.92% and a negative net margin of 217.64%. The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $2.45 million. On average, analysts expect that ProPhase Labs will post -1.27 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen began coverage on shares of ProPhase Labs in a report on Tuesday, February 25th. They issued a “sell” rating for the company.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.